AgingResearch.NewsJoin free

89bio

CompanyUnited StatesFounded 2018

RORWikidata

89bio develops one asset, in phase 3 (pegozafermin in metabolic dysfunction-associated steatohepatitis (mash) / nonalcoholic steatohepatitis (nash) with compensated cirrhosis). Mostly protein or enzyme acting on Insulin/IGF-1 signalling, lipid and ceramide metabolism and KLB; based in the United States, founded in 2018.

1
Asset
Furthest stage
Phase 3
2
Trials
0
Signals

Pipeline

1

  • pegozafermin

    Long-acting glycopegylated FGF21 analog that regulates lipid and glucose metabolism.

    Phase 3, Protein or enzyme, Insulin/IGF-1 signalling, Lipid and ceramide metabolism, metabolic dysfunction-associated steatohepatitis (mash) / nonalcoholic steatohepatitis (nash) with compensated cirrhosis, metabolic dysfunction-associated steatotic liver disease (mash) / nonalcoholic steatohepatitis (nash) with fibrosis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms7
  • Trials2
  • Signals4
  • Similar companies6

Papers

Intelligence